CJC-1295 With DAC vs Without DAC: Understanding the Critical Difference
CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29) are the same peptide backbone with fundamentally different pharmacokinetics. One produces pulsatile GH; the other produces sustained GH elevation. This comparison explains why the distinction matters enormously for research.
CJC-1295 exists in two pharmacologically distinct forms — with and without DAC (Drug Affinity Complex) — with radically different half-lives and GH release profiles. This distinction is one of the most important in GH secretagogue research.
The DAC Technology
DAC is a maleimidoproprionic acid (MPA) derivative attached to Lys³⁸ of CJC-1295. When administered, MPA forms a covalent bond with serum albumin's free Cys³⁴ thiol via Michael addition. Since albumin has a half-life of ~19 days, the albumin-bound complex achieves dramatically extended circulation.
- [CJC-1295 with DAC](/peptides/cjc-1295-dac): Half-life ~6-10 days
- [CJC-1295 without DAC](/peptides/cjc-1295-no-dac) (mod-GRF 1-29): Half-life ~30 minutes
Pharmacological Consequence
[CJC-1295 without DAC](/peptides/cjc-1295-no-dac): Each injection produces a discrete 90-120 minute GH pulse, then returns to baseline. Normal pulsatile GH rhythm is maintained between doses.
[CJC-1295 with DAC](/peptides/cjc-1295-dac): A single injection produces sustained GHRH-R activation for 6-10 days. Teichman SL et al. (*Journal of Clinical Endocrinology & Metabolism*, 2006) demonstrated that a single 2 mg dose maintained GH at 2-5× baseline for 6 days and IGF-1 at 1.5-2× baseline for 9-11 days in healthy adults.
The Axis Physiology Debate
The central research question: is continuous GHRH-R activation physiologically appropriate?
The pituitary GH axis is designed for pulsatile stimulation — discrete GHRH pulses producing GH peaks followed by somatostatin-mediated suppression. Pulsatility is associated with higher hepatic IGF-1 production per unit GH exposure vs continuous GH infusion.
Proponents of CJC-1295 with DAC cite higher IGF-1 elevation, reduced injection frequency (once weekly vs daily), and good tolerability in published studies. Critics argue that continuous GHRH-R activation is physiologically abnormal and may accelerate receptor downregulation. Teichman et al. found no desensitisation evidence over 28 days, but longer-term data is limited.
GH "Bleed" Concern
Continuous GHRH stimulation creates a low-level continuous GH elevation ("GH bleed"). Continuous (vs pulsatile) GH exposure is associated with more side effects in exogenous GH administration. Whether this translates meaningfully for CJC-1295-DAC remains unresolved.
CJC-1295 without DAC and CJC-1295 with DAC are NOT interchangeable. Always confirm which form is being studied or used.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers and a board-certified physician before publication.
Meet the full editorial teamMedically Reviewed by Dr. Amanda Reid, MD
This article has been reviewed by Dr. Amanda Reid, MD (Board-Certified Internal Medicine), Know Your Peptide Medical Advisor, for scientific accuracy, safety information, and appropriate clinical context. Learn about our review process.